Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.
Read more about Immatics on our homepage: https://immatics.com/
Find us also on:
Instagram: https://www.instagram.com/immatics/
YouTube: https://www.youtube.com/channel/UCv7uTpsGXvSNzwSX_xOtYSA
Legal notice: https://immatics.com/imprint/
Company Details
- Employees
- 594
- Founded
- -
- Address
- Paul-Ehrlich-Str. 15, Tuebingen,72076,germany
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- immatics.net
- Keywords
- Discovery of HLA-restricted tumor-associated peptides as cancer targets, Biomarkers, Immunomonitoring, Peptidomics & mass spectrometry, Standardized PBMC collection, Bioinformatics, Immunology, TCR Discovery, Bispecific Development, TCR-based Immunotherapies, Adoptive Cell Therapy, TCR Bispecifics, Cancer.
- HQ
- Tuebingen
Immatics Questions
Immatics's website is immatics.net
Immatics's LinkedIn profile is https://www.linkedin.com/company/immatics
Immatics has
594 employees.
View email and phone details for 594
employees at Immatics.
Immatics's industry is
Biotechnology Research
Immatics's top competitors are
Boehringer Ingelheim,
Biontech Se,
Cellipont Bioservices,
Curevac,
Neurogene Inc.,
Biohouston,
Lonza,
Medigene Ag,
Roche,
Ctmc.
Immatics's categories are Biotechnology Research
Immatics's founding year is 2000
